表紙:バーチャル臨床試験サービスプロバイダーの世界市場:治療領域 (心血管・感染症・代謝疾患・神経疾患・腫瘍・その他) 別
市場調査レポート
商品コード
1001803

バーチャル臨床試験サービスプロバイダーの世界市場:治療領域 (心血管・感染症・代謝疾患・神経疾患・腫瘍・その他) 別

Virtual Clinical Trial Service Providers Market by Type of Therapeutic Area (Cardiovascular disorders, Infectious disorders, Metabolic disorders, Neurological disorders, Oncological disorders and Other disorders),

出版日: | 発行: Roots Analysis | ページ情報: 英文 285 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.12円
バーチャル臨床試験サービスプロバイダーの世界市場:治療領域 (心血管・感染症・代謝疾患・神経疾患・腫瘍・その他) 別
出版日: 2021年01月31日
発行: Roots Analysis
ページ情報: 英文 285 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

新規化合物の開発は大規模なコストと時間がかかる複雑で高度なプロセスです。臨床研究のプロセスは遅延しやすく、非効率的なデータ処理、失敗のリスク、不完全な患者募集など、いくつかの課題を抱えています。また、新型コロナウイルス感染症 (COVID-19) の世界的流行も臨床業務のほぼすべての側面に影響を与えています。長年にわたり、製薬業界は技術の進歩を利用して、これらの制約や課題に対処してきました。そして近年では、臨床試験のさまざまな側面を実施・管理するための幅広いサービスやソリューションを提供する複数のベンダーが参入しています。

バーチャル臨床試験は臨床試験の実施方法にディスラプションをもたらす可能性を秘めています。ソフトウェア・アプリケーション、電子モニター&デバイス、ソーシャルエンゲージメントプラットフォームなどの先進技術ソリューションを導入することで、臨床研究を強化し、効率的な患者の募集、患者の離脱率の減少、確実なデータ分析を可能にし、臨床試験への投資資金を最大25%節約できる可能性があります。また、バーチャル試験に関連するイニシアチブは、民間および公共の投資家から大規模な資金を得ています。医薬品開発プロセスにおいてデジタルソリューションの導入が進んでいることから、バーチャル臨床試験の市場は今後数年で大きく成長する可能性があると考えられます。

当レポートでは、世界のバーチャル臨床試験サービスプロバイダーの市場を調査し、市場および技術・サービスの概要、市場成長への各種影響因子の分析、バーチャル臨床試験サービスプロバイダーの分析、ケーススタディ、市場シェア、プロファイル、資金調達・投資の分析、提携・協力関係の分析、臨床試験の実施動向、市場機会・市場規模の予測、治療領域・開発フェーズ・地域別の内訳などをまとめています。

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

  • 臨床調査における既存の制約
  • バーチャル臨床試験
    • 重要側面
    • 長所・短所
  • 臨床医薬品開発の新たな動向
  • 今後の展望

第4章 バーチャル臨床試験サービスプロバイダー:現在の市場情勢

  • 設立年
  • 企業規模
  • 地域
  • 提供サービス

第5章 企業プロファイル

  • Cambridge Cognition
  • Center Point Clinical Services
  • eClinicalHealth
  • IQVIA
  • Mytrus (Medidata Solutions)
  • PanAmerican Clinical Research
  • Science 37
  • VirTrial

第6章 ケーススタディ:大手医薬品企業のバーチャル臨床試験関連のイニシアチブ

  • Pfizer
  • Johnson & Johnson
  • Sanofi
  • Novartis
  • GlaxoSmithKline
  • Amgen
  • AstraZeneca

第7章 ケーススタディ:従来型・バーチャル型CRO

  • 従来型CRO・バーチャル型CROの比較
  • バーチャル型CROの主な属性
  • バーチャルオペレーティングモデル
  • おわりに

第8章 資金調達・投資分析

  • 資金タイプ
  • バーチャル臨床試験サービスプロバイダー:資金調達・投資分析
    • 投資年
    • 投資額
    • 資金調達タイプ
    • もっともアクティブな事業者
    • もっともアクティブな投資家
  • おわりに

第9章 提携・協力

  • 提携モデル
  • バーチャル臨床試験サービスプロバイダー:提携・協力
    • 提携年
    • 提携タイプ
    • 合意の重点分野
    • 合意の標的治療領域
    • 提携年・提携タイプ
    • もっともアクティブな企業:提携数別
    • 地域分析
    • 大陸間および大陸内協定

第10章 COVID-19の影響

第11章 臨床試験の分析

  • 範囲・調査手法
  • バーチャル臨床試験:臨床試験分析
    • 試験登録年
    • 試験段階
    • 試験ステータス
    • 試験設計
    • スポンサータイプ
    • 対象治療領域
    • 登録試験数:地域分析
    • 登録患者数:地域分析

第12章 市場機会の評価

  • 範囲・調査手法
  • バーチャル臨床試験サービスプロバイダーの市場機会
    • 治療領域別
    • エンドユーザー別
    • 試験段階別
    • 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第13章 結論

第14章 インタビュートランスクリプト

第15章 付録1:集計データ

第16章 付録2:企業・組織リスト

図表

List Of Tables

  • Table 4.1 Virtual Clinical Trial Service Providers: List of Companies
  • Table 4.2 Virtual Clinical Trial Service Providers: Type of Service Offered
  • Table 5.1 Leading Virtual Clinical Trial Service Providers
  • Table 5.2 Cambridge Cognition: Company Snapshot
  • Table 5.3 Cambridge Cognition: Recent Developments and Future Outlook
  • Table 5.4 Center Point Clinical Services: Company Snapshot
  • Table 5.5 Center Point Clinical Services: Recent Developments and Future Outlook
  • Table 5.6 eClinicalHealth: Company Snapshot
  • Table 5.7 eClinicalHealth: Recent Developments and Future Outlook
  • Table 5.8 IQVIA: Company Snapshot
  • Table 5.9 IQVIA: Recent Developments and Future Outlook
  • Table 5.10 Mytrus (Medidata Solutions): Company Snapshot
  • Table 5.11 Mytrus (Medidata Solutions): Recent Developments and Future Outlook
  • Table 5.12 PanAmerican Clinical Research: Company Snapshot
  • Table 5.13 Science 37: Company Snapshot
  • Table 5.14 Science 37: Recent Developments and Future Outlook
  • Table 5.15 VirTrial: Company Snapshot
  • Table 5.16 VirTrial: Recent Developments and Future Outlook
  • Table 6.1 Initiatives in Virtual Trials Domain: Big Pharma Players
  • Table 6.2 Virtual Clinical Trial Sponsors: List of Pharma Players
  • Table 7.1 Traditional Trials versus Virtual Trials
  • Table 8.1 Virtual Clinical Trial Services Market: Funding and Investments, 2014-2020
  • Table 8.2 Funding and Investment Analysis: Summary of Investments
  • Table 9.1 Virtual Clinical Trial Service Providers: Partnership and Collaborations, 2014-2020
  • Table 15.1 Drug Development Costs: Historical Trend (USD Million)
  • Table 15.2 Virtual Clinical Trial Service Providers: Distribution by Year of Establishment
  • Table 15.3 Virtual Clinical Trial Service Providers: Distribution by Company Size
  • Table 15.4 Virtual Clinical Trial Service Providers: Distribution by Location of Headquarters
  • Table 15.5 Virtual Clinical Trial Service Providers: Distribution by Type of Services Offered
  • Table 15.6 Cambridge Cognition: Annual Revenues, 2016-H1 2020 (GBP Million)
  • Table 15.7 IQVIA: Annual Revenues, 2017-2019 (USD Billion)
  • Table 15.8 Funding and Investment Analysis: Cumulative Number of Instances by Year, 2014-2020
  • Table 15.9 Funding and Investment Analysis: Cumulative Amount Invested, 2014-2020 (USD Million)
  • Table 15.10 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2014-2020
  • Table 15.11 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, 2014-2020 (USD Million)
  • Table 15.12 Funding and Investment Analysis: Most Active Players, 2014-2020 (USD Million)
  • Table 15.13 Funding and Investment Analysis: Most Active Investors, 2014-2020
  • Table 15.14 Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-2020
  • Table 15.15 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 15.16 Partnerships and Collaborations: Distribution by Focus Area Mentioned in Agreement
  • Table 15.17 Partnerships and Collaborations: Distribution by Target Therapeutic Area
  • Table 15.18 Partnerships and Collaborations: Distribution by Year and Type of Partner
  • Table 15.19 Partnerships and Collaborations: Most Active Players
  • Table 15.20 Partnership and Collaborations: Country-wise Distribution
  • Table 15.21 Clinical Trial Analysis: Distribution by Trial Registration Year
  • Table 15.22 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year
  • Table 15.23 Clinical Trial Analysis: Distribution by Trial Status
  • Table 15.24 Clinical Trial Analysis: Distribution by Type of Sponsor
  • Table 15.25 Clinical Trial Analysis: Distribution by Target Therapeutic Area
  • Table 15.26 Clinical Trial Analysis: Distribution by Target Indication
  • Table 15.27 Clinical Trial Analysis: Distribution by Study Design
  • Table 15.28 Clinical Trial Analysis: Most Active Players
  • Table 15.29 Global Virtual Clinical Trial Service Providers Market, Conservative, Base and Optimistic Scenarios, 2020-2050 (USD Billion)
  • Table 15.30 Virtual Clinical Trial Service Providers Market: Distribution by Target Therapeutic Area, Conservative, Base and Optimistic Scenarios, 2020, 2035 and 2050 (USD Million)
  • Table 15.31 Virtual Clinical Trial Service Providers Market: Distribution by Phase of Development, Conservative, Base and Optimistic Scenarios, 2020, 2035 and 2050 (USD Million)
  • Table 15.32 Virtual Clinical Trial Service Providers Market: Distribution by Geography, Conservative, Base and Optimistic Scenarios, 2020, 2035 and 2050 (USD Million)
  • Table 15.33 Virtual Clinical Trial Service Providers Market Opportunity in North America, Conservative, Base and Optimistic Scenarios, 2020-2050 (USD Billion)
  • Table 15.34 Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050 (USD Million)
  • Table 15.35 Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
  • Table 15.36 Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
  • Table 15.37 Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
  • Table 15.38 Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
  • Table 15.39 Virtual Clinical Trial Services Market for CNS Disorders in North America, 2020-2050 (USD Million)
  • Table 15.40 Virtual Clinical Trial Services Market for CNS Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
  • Table 15.41 Virtual Clinical Trial Services Market for CNS Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
  • Table 15.42 Virtual Clinical Trial Services Market for CNS Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
  • Table 15.43 Virtual Clinical Trial Services Market for CNS Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
  • Table 15.44 Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050 (USD Million)
  • Table 15.45 Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
  • Table 15.46 Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
  • Table 15.47 Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
  • Table 15.48 Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
  • Table 15.49 Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050 (USD Million)
  • Table 15.50 Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
  • Table 15.51 Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
  • Table 15.52 Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
  • Table 15.53 Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
  • Table 15.54 Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050 (USD Million)
  • Table 15.55 Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
  • Table 15.56 Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
  • Table 15.57 Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
  • Table 15.58 Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
  • Table 15.59 Virtual Clinical Trial Services Market for Respiratory Disorders in North America, 2020-2050 (USD Million)
  • Table 15.60 Virtual Clinical Trial Services Market for Respiratory Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
  • Table 15.61 Virtual Clinical Trial Services Market for Respiratory Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
  • Table 15.62 Virtual Clinical Trial Services Market for Respiratory Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
  • Table 15.63 Virtual Clinical Trial Services Market for Respiratory Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
  • Table 15.64 Virtual Clinical Trial Services Market for Other Disorders in North America, 2020-2050 (USD Million)
  • Table 15.65 Virtual Clinical Trial Services Market for Other Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
  • Table 15.66 Virtual Clinical Trial Services Market for Other Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
  • Table 15.67 Virtual Clinical Trial Services Market for Other Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
  • Table 15.68 Virtual Clinical Trial Services Market for Other Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
  • Table 15.69 Virtual Clinical Trial Service Providers Market Opportunity in Europe, Conservative, Base and Optimistic Scenarios, 2020-2050 (USD Billion)
  • Table 15.70 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050 (USD Million)
  • Table 15.71 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
  • Table 15.72 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
  • Table 15.73 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
  • Table 15.74 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
  • Table 15.75 Virtual Clinical Trial Services Market for CNS Disorders in Europe, 2020-2050 (USD Million)
  • Table 15.76 Virtual Clinical Trial Services Market for CNS Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
  • Table 15.77 Virtual Clinical Trial Services Market for CNS Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
  • Table 15.78 Virtual Clinical Trial Services Market for CNS Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
  • Table 15.79 Virtual Clinical Trial Services Market for CNS Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
  • Table 15.80 Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050 (USD Million)
  • Table 15.81 Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
  • Table 15.82 Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
  • Table 15.83 Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
  • Table 15.84 Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
  • Table 15.85 Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050 (USD Million)
  • Table 15.86 Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
  • Table 15.87 Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
  • Table 15.88 Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
  • Table 15.89 Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
  • Table 15.90 Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050 (USD Million)
  • Table 15.91 Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
  • Table 15.92 Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
  • Table 15.93 Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
  • Table 15.94 Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
  • Table 15.95 Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050 (USD Million)
  • Table 15.96 Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
  • Table 15.97 Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
  • Table 15.98 Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
  • Table 15.99 Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
  • Table 15.100 Virtual Clinical Trial Services Market for Other Disorders in Europe, 2020-2050 (USD Million)
  • Table 15.101 Virtual Clinical Trial Services Market for Other Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
  • Table 15.102 Virtual Clinical Trial Services Market for Other Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
  • Table 15.103 Virtual Clinical Trial Services Market for Other Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
  • Table 15.104 Virtual Clinical Trial Services Market for Other Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
  • Table 15.105 Virtual Clinical Trial Service Providers Market Opportunity in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2020-2050 (USD Billion)
  • Table 15.106 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050 (USD Million)
  • Table 15.107 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
  • Table 15.108 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
  • Table 15.109 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
  • Table 15.110 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
  • Table 15.111 Virtual Clinical Trial Services Market for CNS Disorders in Asia-Pacific, 2020-2050 (USD Million)
  • Table 15.112 Virtual Clinical Trial Services Market for CNS Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
  • Table 15.113 Virtual Clinical Trial Services Market for CNS Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
  • Table 15.114 Virtual Clinical Trial Services Market for CNS Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
  • Table 15.115 Virtual Clinical Trial Services Market for CNS Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
  • Table 15.116 Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050 (USD Million)
  • Table 15.117 Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
  • Table 15.118 Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
  • Table 15.119 Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
  • Table 15.120 Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
  • Table 15.121 Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050 (USD Million)
  • Table 15.122 Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
  • Table 15.123 Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
  • Table 15.124 Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
  • Table 15.125 Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
  • Table 15.126 Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050 (USD Million)
  • Table 15.127 Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
  • Table 15.128 Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
  • Table 15.129 Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
  • Table 15.130 Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
  • Table 15.131 Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050 (USD Million)
  • Table 15.132 Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
  • Table 15.133 Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
  • Table 15.134 Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
  • Table 15.135 Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
  • Table 15.136 Virtual Clinical Trial Services Market for Other Disorders in Asia-Pacific, 2020-2050 (USD Million)
  • Table 15.137 Virtual Clinical Trial Services Market for Other Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
  • Table 15.138 Virtual Clinical Trial Services Market for Other Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
  • Table 15.139 Virtual Clinical Trial Services Market for Other Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
  • Table 15.140 Virtual Clinical Trial Services Market for Other Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
  • Table 15.141 Virtual Clinical Trial Service Providers Market Opportunity in Rest of the World, Conservative, Base and Optimistic Scenarios, 2020-2050 (USD Billion)
  • Table 15.142 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050 (USD Million)
  • Table 15.143 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
  • Table 15.144 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
  • Table 15.145 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
  • Table 15.146 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
  • Table 15.147 Virtual Clinical Trial Services Market for CNS Disorders in Rest of the World, 2020-2050 (USD Million)
  • Table 15.148 Virtual Clinical Trial Services Market for CNS Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
  • Table 15.149 Virtual Clinical Trial Services Market for CNS Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
  • Table 15.150 Virtual Clinical Trial Services Market for CNS Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
  • Table 15.151 Virtual Clinical Trial Services Market for CNS Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
  • Table 15.152 Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050 (USD Million)
  • Table 15.153 Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
  • Table 15.154 Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
  • Table 15.155 Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
  • Table 15.156 Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
  • Table 15.157 Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050 (USD Million)
  • Table 15.158 Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
  • Table 15.159 Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
  • Table 15.160 Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
  • Table 15.161 Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
  • Table 15.162 Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050 (USD Million)
  • Table 15.163 Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
  • Table 15.164 Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
  • Table 15.165 Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
  • Table 15.166 Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
  • Table 15.167 Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050 (USD Million)
  • Table 15.168 Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
  • Table 15.169 Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
  • Table 15.170 Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
  • Table 15.171 Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
  • Table 15.172 Virtual Clinical Trial Services Market for Other Disorders in Rest of the World, 2020-2050 (USD Million)
  • Table 15.173 Virtual Clinical Trial Services Market for Other Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
  • Table 15.174 Virtual Clinical Trial Services Market for Other Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
  • Table 15.175 Virtual Clinical Trial Services Market for Other Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
  • Table 15.176 Virtual Clinical Trial Services Market for Other Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)

List Of Companies

The following companies and organizations have been included in the report:

  • 1. Academic Medical Center Amsterdam
  • 2. ACRP
  • 3. Advarra
  • 4. AiCure
  • 5. Alacris Theranostics
  • 6. AliveCor
  • 7. Andaman7
  • 8. Aparito
  • 9. AstraZeneca
  • 10. Atlantic General Hospital
  • 11. BARDA
  • 12. BetterLife
  • 13. BioIntelliSense
  • 14. Boehringer Ingelheim
  • 15. CAIMED
  • 16. Cambridge Cognition
  • 17. Cancer Hope Network
  • 18. Castor
  • 19. Center Point Clinical Services
  • 20. City of Hope Medical Center
  • 21. Click Therapeutics
  • 22. ClinCloud Tech
  • 23. Clinerion
  • 24. Clinical Ink
  • 25. Clinical Trials Transformation Initiative
  • 26. ClinOne
  • 27. ConsilX
  • 28. Covance
  • 29. Covance
  • 30. Cquentia
  • 31. Ctrl Group
  • 32. Datavant
  • 33. Delve Health
  • 34. Dreem
  • 35. DxTerity
  • 36. eClinicalHealth
  • 37. Elektra Labs
  • 38. Eli Lilly
  • 39. EmpiraMed
  • 40. ERT
  • 41. Evidation
  • 42. Foundation Medicine
  • 43. GI Partners
  • 44. Harte Group
  • 45. Healint
  • 46. i3 Consult
  • 47. iClinical
  • 48. IDD Research
  • 49. IQVIA
  • 50. ISBX
  • 51. Jeeva Informatics
  • 52. Kinsights
  • 53. KiwiTech
  • 54. LabCorp
  • 55. LabCorp
  • 56. Medable
  • 57. Medikit
  • 58. Medocity
  • 59. Medpoint Digital
  • 60. monARC Bionetworks
  • 61. MRN
  • 62. Myovant Sciences
  • 63. Medidata Solutions
  • 64. Novartis
  • 65. ObvioHealth
  • 66. Otsuka Pharmaceutical
  • 67. PanAmerican Clinical Research
  • 68. PPMD
  • 69. Redox
  • 70. Roivant
  • 71. Sage Bionetworks
  • 72. Sanofi
  • 73. Sanofi
  • 74. Sarcoma Alliance
  • 75. Science 37
  • 76. Signant Health
  • 77. SnapIoT
  • 78. Studies&Me
  • 79. Synevo Central Labs
  • 80. Synexus
  • 81. THREAD Research
  • 82. Transparency Life Sciences
  • 83. UBC
  • 84. UCB
  • 85. Unnamed CRO
  • 86. Unnamed Pharmaceutiical Company
  • 87. Virtrial
  • 88. VisualDx
  • 89. Vsee
  • 90. Wellcome Trust
  • 91. xCures
目次

Title:
Virtual Clinical Trial Service Providers
Market by Type of Therapeutic Area (Cardiovascular disorders, Infectious disorders, Metabolic disorders, Neurological disorders, Oncological disorders and Other disorders), End-Users (Small-sized players, Mid-sized players, Large players and Academia / Others), Phase of Development (Phase I, Phase II, Phase III and Phase IV), and Key Geographies (North America, Europe, Asia Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2020-2050.

Overview:

Owing to its highly cost and time intensive nature, the development of a novel molecular entity is a complex and sophisticated process. In fact, it is estimated that before receiving regulatory approval, a prescription drug requires more than 10 years and close to USD 3 billion in capital investment. Additionally, close to 40% of the pharmaceutical industry's R&D budget in the US is spent on conducting clinical trials assessing the efficacy of novel treatments. With rising geographical diversity in clinical trials, the trial complexity is increasing rapidly in this domain making it difficult for trial coordinators to identify sub-optimal trial sites. It is worth highlighting that, the clinical research process is known to be prone to delays, and often faces several other challenges, including (but not limited to) inefficient data handling, risk of failure and incomplete patient recruitment, which can be validated from the fact that only 10% of drug candidates under clinical development receive regulatory approval. The lack of patient centricity in traditional clinical trials inhibit trial sponsors to retain enough patients, which is critical to successfully conduct clinical research on predetermined completion dates. The lack of participant compliance in clinical trials often leads to massive delays which are known to impose enormous financial burden on sponsors, amounting close to USD 8 million, per day, blockbuster drugs. Another noticeable concern in this domain, is the inefficient handling of clinical data, which is primarily due insignificant use electronic health records. Estimates indicate that, the pharmaceutical industry incurs losses of USD 6 billion each year due to such avoidable data-related concerns. In addition, the COVID-19 pandemic has impacted nearly all aspects of clinical operations being conducted across the world.

Over the years, the pharmaceutical industry has leveraged technological advances to address several of the aforementioned clinical trial-related constraints / challenges. In fact, the clinical research segment has recently witnessed participation of several vendors, offering wide range of services and solutions for conducting and managing various aspects of trials. Virtual clinical trials have demonstrated the potential to disrupt the conventional ways of conducting trials, allowing sponsors to establish a more patient centric approach to drug development. Virtual clinical trial technologies augment clinical research by implementation of advanced technological solutions, including (but not limited to) software applications, e-monitoring devices and social engagement platforms. Such solutions hold the potential to save up to 25% of capital invested in clinical trials, by enabling efficient patient recruitment, reduction in patient attrition rate and robust data analysis. It is worth noting that, virtual trials related initiatives have also received significant funding from both private and public investors. With digital solutions witnessing increased adoption in the drug development process, we are led to believe that the virtual clinical trials market is likely to grow significantly in the coming years.

Scope of the Report:

The “Virtual Clinical Trial Service Providers Market, 2020-2050: Distribution by Type of Therapeutic Area (Cardiovascular Disorders, CNS Disorders, Infectious Disorders, Metabolic Disorders, Oncological Disorders, Respiratory Disorders and Other Disorders, Phase of Development (Phase I, Phase II, Phase III and Phase IV), and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World) ” report features an extensive study of the current landscape of industry players that are offering various types of innovative clinical research platforms / solutions to the pharmaceutical and life sciences industries. Amongst other elements, the report features:

  • An overview of the current market landscape of companies offering solutions for virtual clinical trials, featuring information on year of establishment, geographical location, company size and types of services offered (study start-up, patient enrollment, drug logistics, data collection and analysis, and patient retention).
  • Brief profiles of companies offering solutions for virtual clinical trials, featuring information on their year of establishment, respective headquarters, company size, key executives, service / technology portfolio, recent developments and an informed future outlook.
  • A case study on the initiatives of big pharma players related to virtual clinical trials, offering insights on such clinical studies that have been conducted / planned by the aforementioned players, along with details on associated constraints and the future plans of players engaged in this domain.
  • An analysis of the funding and investments made in the domain, in the period between 2014 and 2020 (till November), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are engaged in this field, based on several parameters, such as number of funding instances, amount invested, type of funding, leading players and investors, and geographical analysis.
  • An analysis of the partnerships and collaborations inked in the domain, in the period between 2014 and 2020 (till November), based on several parameters, such as year of partnership, type of partnership, application mentioned in agreement, target therapeutic area mentioned in the agreement, type of partner, most active players and geographical analysis.
  • A detailed study highlighting the key differences between traditional and virtual CROs and an elaborate road map, presenting the requirements for a traditional CRO to transition to a virtual CRO business model.
  • A brief case study highlighting the impact of COVID-19 pandemic on virtual clinical trial service providers market.
  • A detailed analysis of completed, ongoing and planned virtual clinical trials, based on multiple parameters, such as trial registration year, trial phase, trial status, type of sponsor / collaborator, target therapeutic area, trial design, top sponsor, geographical location of trial and enrolled patient population.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future opportunity of the market for virtual clinical trial services. Based on parameters, such as number of pre- or post-approval studies conducted annually, capital investments made in these studies, and the likely cost and time saving opportunities, we have provided an informed estimate of the likely evolution of the market for virtual clinical trials, for the period 2020-2050. The report also features the likely distribution of the current and forecasted opportunity across [A] different therapeutic areas (cardiovascular disorders, infectious disorders, metabolic disorders, neurological disorders, oncological disorders and others), [B] phase of development (phase I, phase II, phase III and phase IV) and [C] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. In addition, the report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company names):

  • Phillipe Lemmens (Chief Operating Officer, Andaman7)
  • Himanshu Verma (Founder and Chief Executive Officer, ConsilX) and Rajesh Jain (Co-Founder, ConsilX)
  • Greg Erman (President and Chief Executive Officer, EmpiraMed)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • Who are the leading virtual clinical trial service providers?
  • Which companies have raised significant capital in this domain?
  • How can traditional CRO transition to virtual CRO?
  • What factors are likely to influence the evolution of this upcoming market?
  • How is the current and future opportunity likely to be distributed across key market segments?

Chapter Outlines:

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the virtual clinical trial service providers market, in the mid to long term.

Chapter 3 presents a general overview of the investment, in terms of time and cost, required for developing new healthcare products, along with information on other constraints associated with clinical research, including patient recruitment and retention, evolving regulatory standards and inefficient data handling. Further, it features a detailed outline on the various upcoming trends that are anticipated to play a crucial role in shaping the future of clinical trials, including increasing focus on patient centricity, precision medicine, real-world evidence, big data analytics, virtual clinical trials, innovative trial designs and blockchain-based platforms.

Chapter 4 provides a list of industry players that are actively involved in offering services for virtual clinical trials. The chapter presents analyses of these players based on year of establishment, geographical location, company size and types of services offered (study start-up, patient enrollment, drug logistics, data collection and analysis, and patient retention).

Chapter 5 features brief profiles of companies offering solutions for virtual clinical trials, featuring information on their year of establishment, respective headquarters, company size, key executives, service / technology portfolio, recent developments and an informed future outlook.

Chapter 6 is a case study on the initiatives of big pharma companies related to virtual clinical trials, offering insights on such clinical studies that have been conducted / planned by the aforementioned players, along with details on associated constraints and the future plans of players engaged in this domain.

Chapter 7 provides an analysis of the funding and investments made in the domain, in the period between 2014 and 2020 (till November), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are engaged in this field, based on several parameters, such as number of funding instances, amount invested, type of funding, leading players and investors, and geographical analysis.

Chapter 8 provides an analysis of the partnerships and collaborations inked in the domain, in the period between 2014 and 2020 (till November), based on several parameters, such as year of partnership, type of partnership, application mentioned in agreement, target therapeutic area mentioned in the agreement, year of partnership and type of partner, most active players and geographical analysis.

Chapter 9 provides a detailed study highlighting the key differences between traditional and virtual CROs and an elaborate road map, presenting the requirements for a traditional CRO to transition to a virtual CRO business model.

Chapter 10 provides an insightful discussion on the impact of COVID-19 pandemic on the virtual clinical trial service providers market.

Chapter 11 provides a detailed analysis of completed, ongoing and planned virtual clinical trials, based on multiple parameters, such as trial registration year, trial phase, trial status, type of sponsor / collaborator, target therapeutic area, trial design, top sponsor, geographical location of trial and enrolled patient population.

Chapter 12 provides an insightful opportunity analysis, estimating the existing market size and potential growth opportunities across service providers working in virtual clinical trials. Based on multiple parameters, such as number of studies conducted annually, investment associated with these studies, and the likely cost and time saving opportunities, we have provided an informed estimate on the likely evolution of the market over the period 2020-2050. The report also features the likely distribution of the current and forecasted opportunity across [A] different therapeutic areas (cardiovascular disorders, infectious disorders, metabolic disorders, neurological disorders, oncological disorders and others), [B] end-users (small-sized players, mid-sized players, large players and academia / others) [C] phase of development (phase I, phase II, phase III and phase IV) and [D] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World).

Chapter 13 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it summarizes the various evolutionary trends that are likely to influence the future of virtual clinical trials service providers market.

Chapter 14 is a collection of interview transcripts of discussions held with key stakeholders in this market. We have presented the details of our discussions with (in alphabetical order of company names) Phillipe Lemmens (Chief Operating Officer, Andaman7), Himanshu Verma (Founder and Chief Executive Officer, ConsilX), Rajesh Jain (Co-Founder, ConsilX) and Greg Erman (President and Chief Executive Officer, EmpiraMed).

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 16 is an appendix, which contains the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Existing Constraints in Clinical Research
    • 3.2.1. Increasing Complexity and Cost of Trials
    • 3.2.2. Evolving Regulatory Standards
    • 3.2.3. Patient Recruitment and Retention Challenges
    • 3.2.4. Data Handling-related Concerns
  • 3.3. Virtual Clinical Trials
    • 3.3.1. Key Aspects of Virtual Clinical Trials
      • 3.3.1.1. Study Design
      • 3.3.1.2. Patient Recruitment and Retention
      • 3.3.1.3. Remote Monitoring
      • 3.4.1.4. Data Collection and Analysis
    • 3.3.2. Advantages and Disadvantages of Virtual Clinical Trials
  • 3.4. Emerging Trends in Clinical Drug Development
    • 3.4.1. Innovative Trial Designs
    • 3.4.2. Real-world Evidence
    • 3.4.3. Patient Centricity
    • 3.4.4. Big Data Analytics
    • 3.4.5. Blockchain Technology
  • 3.5. Future Perspectives

4. VIRTUAL CLINICAL TRIAL SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE

1. Chapter Overview

  • 4.2. Virtual Clinical Trial Service Providers: Overall Market Overview
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Geography
    • 4.2.4. Analysis by Type of Service Offered

5. COMPANY PROFILES

  • 5.1. Chapter Overview
  • 5.2. Cambridge Cognition
    • 5.2.1. Company Overview
    • 5.2.2. Technology Overview
    • 5.2.3. Recent Developments and Future Outlook
  • 5.3. Center Point Clinical Services
    • 5.3.1. Company Overview
    • 5.3.2. Technology Overview
  • 3.3. Recent Developments and Future Outlook
  • 5.4. eClinicalHealth
    • 5.4.1. Company Overview
    • 5.4.2. Technology Overview
    • 5.4.3. Recent Developments and Future Outlook
  • 5.5. IQVIA
    • 5.5.1. Company Overview
    • 5.5.2. Technology Overview
    • 5.5.3. Recent Developments and Future Outlook
  • 5.6. Mytrus (Medidata Solutions)
    • 5.6.1. Company Overview
    • 5.6.2. Technology Overview
    • 5.6.3. Recent Developments and Future Outlook
  • 5.7. PanAmerican Clinical Research
    • 5.7.1. Company Overview
    • 5.7.2. Technology Overview
    • 5.7.3. Recent Developments and Future Outlook
  • 5.8. Science 37
    • 5.8.1. Company Overview
    • 5.8.2. Technology Overview
    • 5.8.3. Recent Developments and Future Outlook
  • 5.9. VirTrial
    • 5.9.1. Company Overview
    • 5.9.2. Technology Overview
    • 5.9.3. Recent Developments and Future Outlook

6. CASE STUDY: VIRTUAL CLINICAL TRIAL-RELATED INITIATIVES OF BIG PHARMA PLAYERS

  • 6.1. Chapter Overview
  • 6.2. Virtual Clinical Trial-Related Initiatives of Big Pharma Players
    • 6.2.1. Pfizer
      • 6.2.1.1. Initial Approach and Key Learnings
      • 6.2.1.2. Future Perspective
    • 6.2.2. Johnson & Johnson
      • 6.2.2.1. Initial Approach and Key Learnings
      • 6.2.2.2. Future Perspective
    • 6.2.3. Sanofi
      • 6.2.3.1. Initial Approach and Key Learnings
      • 6.2.3.2. Future Perspective
    • 6.2.4. Novartis
      • 6.2.4.1. Initial Approach and Key Learnings
      • 6.2.4.2. Future Perspective
    • 6.2.5. GlaxoSmithKline
      • 6.2.5.1. Initial Approach and Key Learnings
      • 6.2.5.2. Future Perspective
    • 6.2.6. Amgen
      • 6.2.6.1. Initial Approach and Key Learnings
      • 6.2.6.2. Future Perspective
    • 6.2.7. AstraZeneca
      • 6.2.7.1. Initial Approach and Key Learnings
      • 6.2.7.2. Future Perspective

7. CASE STUDY: TRADITIONAL VERSUS VIRTUAL CRO

  • 7.1. Chapter Overview
  • 7.2. Comparison between Traditional and Virtual CROs
  • 7.3. Key Attributes of a Virtual CRO
  • 7.4. The Virtual Operating Model
  • 7.5. Concluding Remarks

8. FUNDING AND INVESTMENT ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Types of Funding
  • 8.3. Virtual Clinical Trial Service Providers: Funding and Investment Analysis
    • 8.3.1. Analysis by Year of Investment
    • 8.3.2. Analysis by Amount Invested
    • 8.3.3. Analysis by Type of Funding
    • 8.3.4. Most Active Players
    • 8.3.5. Most Active Investors
  • 8.4. Concluding Remarks

9. PARTNERSHIPS & COLLABORATIONS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models
  • 9.3. Virtual Clinical Trial Service Providers: Partnership and Collaborations
    • 9.3.1. Analysis by Year of Partnership
    • 9.3.2. Analysis by Type of Partnership
    • 9.3.3. Analysis by Focus Area Mentioned in Agreement
    • 9.3.4. Analysis by Target Therapeutic Area Mentioned in Agreement
    • 9.3.5. Analysis by Year of Partnership and Type of Partner
    • 9.3.6. Most Active Players: Analysis by Number of Partnerships
    • 9.3.7. Geographical Analysis
    • 9.3.9. Intercontinental and Intracontinental Agreements

10. COVID-19 IMPACT

  • 10.1. Chapter Overview
  • 10.2. Impact of COVID-19 on Clinical Trials
  • 10.3. Impact on Future Opportunity for Virtual Clinical Trials Service Providers

11. CLINICAL TRIAL ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Scope and Methodology
  • 11.3. Virtual Clinical Trials: Clinical Trial Analysis
    • 11.3.1. Analysis by Trial Registration Year
    • 11.3.2. Analysis by Trial Phase
    • 11.3.3. Analysis by Trial Status
    • 11.3.4. Analysis by Trial Design
    • 11.3.5. Analysis by Type of Sponsor
    • 11.3.6. Analysis by Target Therapeutic Area
    • 11.3.7. Geographical Analysis by Number of Registered Trials
    • 11.3.8. Geographical Analysis by Number of Patients Enrolled

12. MARKET OPPORTUNITY ASSESSMENT

  • 12.1. Chapter Overview
  • 12.2. Key Assumptions and Forecast Methodology
  • 12.3. Virtual Clinical Trial Service Providers: Overall Market Opportunity, 2020-2050
    • 12.3.1. Virtual Clinical Trial Service Providers Market Opportunity, 2020-2050: Distribution by Therapeutic Area
    • 12.3.2. Virtual Clinical Trials Service Providers Market Opportunity, 2020-2050: Distribution by End-user
    • 12.3.3. Virtual Clinical Trials Service Providers Market Opportunity, 2020-2050: Distribution by Trial Phase
    • 12.3.4. Virtual Clinical Trials Service Providers Market Opportunity, 2020-2050: Distribution by Geography
  • 12.4. Virtual Clinical Trial Services Market in North America, 2020-2050
    • 12.4.1. Virtual Clinical Trial Services Market in North America: Distribution by Therapeutic Area, 2020-2050
      • 12.4.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050
        • 12.4.1.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase I Studies
        • 12.4.1.1.2. Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase II Studies
        • 12.4.1.1.3. Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase III Studies
        • 12.4.1.1.4. Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase IV Studies
      • 12.4.2.1. Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050
        • 12.4.2.1.1. Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase I Studies
        • 12.4.2.1.2. Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase II Studies
        • 12.4.2.1.3. Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase III Studies
        • 12.4.2.1.4. Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase IV Studies
      • 12.4.3.1. Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050
        • 12.4.3.1.1. Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase I Studies
        • 12.4.3.1.2. Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase II Studies
        • 12.4.3.1.3. Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase III Studies
        • 12.4.3.1.4. Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase IV Studies
      • 12.4.4.1. Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050
        • 12.4.4.1.1. Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase I Studies
        • 12.4.4.1.2. Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase II Studies
        • 12.4.4.1.3. Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase III Studies
        • 12.4.4.1.4. Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase IV Studies
      • 12.4.5.1. Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050
        • 12.4.5.1.1. Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase I Studies
        • 12.4.5.1.2. Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase II Studies
        • 12.4.5.1.3. Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase III Studies
        • 12.4.5.1.4. Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase IV Studies
      • 12.4.6.1. Virtual Clinical Trial Services Market for Respiratory Disorders in North America, 2020-2050
        • 12.4.6.1.1. Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase I Studies
        • 12.4.6.1.2. Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase II Studies
        • 12.4.6.1.3. Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase III Studies
        • 12.4.6.1.4. Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase IV Studies
      • 12.4.7.1. Virtual Clinical Trial Services Market for Other Therapeutic Areas in North America, 2020-2050
        • 12.4.7.1.1. Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase I Studies
        • 12.4.7.1.2. Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase II Studies
        • 12.4.7.1.3. Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase III Studies
        • 12.4.7.1.4. Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase IV Studies
  • 12.5. Virtual Clinical Trial Services Market in Europe, 2020-2050
    • 12.5.1. Virtual Clinical Trial Services Market in Europe: Distribution by Therapeutic Area, 2020-2050
      • 12.5.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050
        • 12.5.1.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase I Studies
        • 12.5.1.1.2. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase II Studies
        • 12.5.1.1.3. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase III Studies
        • 12.5.1.1.4. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase IV Studies
      • 12.5.2.1. Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050
        • 12.5.2.1.1. Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase I Studies
        • 12.5.2.1.2. Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase II Studies
        • 12.5.2.1.3. Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase III Studies
        • 12.5.2.1.4. Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase IV Studies
      • 12.5.3.1. Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050
        • 12.5.3.1.1. Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase I Studies
        • 12.5.3.1.2. Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase II Studies
        • 12.5.3.1.3. Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase III Studies
        • 12.5.3.1.4. Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase IV Studies
      • 12.5.4.1. Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050
        • 12.5.4.1.1. Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase I Studies
        • 12.5.4.1.2. Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase II Studies
        • 12.5.4.1.3. Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase III Studies
        • 12.5.4.1.4. Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase IV Studies
      • 12.5.5.1. Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050
        • 12.5.5.1.1. Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase I Studies
        • 12.5.5.1.2. Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase II Studies
        • 12.5.5.1.3. Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase III Studies
        • 12.5.5.1.4. Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase IV Studies
      • 12.5.6.1. Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050
        • 12.5.6.1.1. Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase I Studies
        • 12.5.6.1.2. Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase II Studies
        • 12.5.6.1.3. Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase III Studies
        • 12.5.6.1.4. Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase IV Studies
      • 12.5.7.1. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050
        • 12.5.7.1.1. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase I Studies
        • 12.5.7.1.2. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase II Studies
        • 12.5.7.1.3. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase III Studies
        • 12.5.7.1.4. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase IV Studies
  • 12.6. Virtual Clinical Trial Services Market in Asia-Pacific, 2020-2050
    • 12.6.1. Virtual Clinical Trial Services Market in Asia-Pacific: Distribution by Therapeutic Area, 2020-2050
      • 12.6.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050
        • 12.6.1.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies
        • 12.6.1.1.2. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies
        • 12.6.1.1.3. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies
        • 12.6.1.1.4. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies
      • 12.6.2.1. Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050
        • 12.6.2.1.1. Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies
        • 12.6.2.1.2. Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies
        • 12.6.2.1.3. Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies
        • 12.6.2.1.4. Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies
      • 12.6.3.1. Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050
        • 12.6.3.1.1. Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies
        • 12.6.3.1.2. Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies
        • 12.6.3.1.3. Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies
        • 12.6.3.1.4. Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies
      • 12.6.4.1. Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050
        • 12.6.4.1.1. Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies
        • 12.6.4.1.2. Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies
        • 12.6.4.1.3. Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies
        • 12.6.4.1.4. Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies
      • 12.6.5.1. Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050
        • 12.6.5.1.1. Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies
        • 12.6.5.1.2. Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies
        • 12.6.5.1.3. Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies
        • 12.6.5.1.4. Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies
      • 12.6.6.1. Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050
        • 12.6.6.1.1. Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies
        • 12.6.6.1.2. Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies
        • 12.6.6.1.3. Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies
        • 12.6.6.1.4. Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies
      • 12.6.7.1. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050
        • 12.6.7.1.1. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase I Studies
        • 12.6.7.1.2. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase II Studies
        • 12.6.7.1.3. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase III Studies
        • 12.6.7.1.4. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase IV Studies
  • 12.7. Virtual Clinical Trial Services Market in Rest of the World, 2020-2050
    • 12.7.1. Virtual Clinical Trial Services Market in Rest of the World: Distribution by Therapeutic Area, 2020-2050
      • 12.7.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050
        • 12.7.1.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase I Studies
        • 12.7.1.1.2. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase II Studies
        • 12.7.1.1.3. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase III Studies
        • 12.7.1.1.4. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies
      • 12.7.2.1. Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050
        • 12.7.2.1.1. Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase I Studies
        • 12.7.2.1.2. Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase II Studies
        • 12.7.2.1.3. Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase III Studies
        • 12.7.2.1.4. Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies
      • 12.7.3.1. Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050
        • 12.7.3.1.1. Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase I Studies
        • 12.7.3.1.2. Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase II Studies
        • 12.7.3.1.3. Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase III Studies
        • 12.7.3.1.4. Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies
      • 12.7.4.1. Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050
        • 12.7.4.1.1. Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase I Studies
        • 12.7.4.1.2. Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase II Studies
        • 12.7.4.1.3. Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase III Studies
        • 12.7.4.1.4. Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies
      • 12.7.5.1. Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050
        • 12.7.5.1.1. Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase I Studies
        • 12.7.5.1.2. Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase II Studies
        • 12.7.5.1.3. Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase III Studies
        • 12.7.5.1.4. Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies
      • 12.7.6.1. Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050
        • 12.7.6.1.1. Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase I Studies
        • 12.7.6.1.2. Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase II Studies
        • 12.7.6.1.3. Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase III Studies
        • 12.7.6.1.4. Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies
      • 12.7.7.1. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050
        • 12.7.7.1.1. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase I Studies
        • 12.7.7.1.2. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase II Studies
        • 12.7.7.1.3. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase III Studies
        • 12.7.7.1.4. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase IV Studies

13. CONCLUSION

14. INTERVIEW TRANSCRIPTS

  • 14.1. Chapter Overview
  • 14.2. ConsilX
    • 14.2.1. Interview Transcript: Himanshu Verma, Founder and Chief Executive Officer, ConsilX & Rajesh Jain, Co-Founder, ConsilX
  • 14.3. EmpiraMed
    • 14.3.1. Interview Transcript: Greg Erman, President and Chief Executive Officer, EmpiraMed
  • 14.4. Andaman7
    • 14.4.1. Interview Transcript: Phillipe Lemmens, Chief Operating Officer, Andaman7
  • 14.5. uMotif
    • 14.5.1. Interview Transcript: Jonathan Moshinsky, Head of Market Strategy, uMotif

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 3.1 Existing Constraints in Clinical Research
  • Figure 3.2 Drug Development Costs: Historical Trend (USD Million)
  • Figure 3.3 Virtual Trial Model
  • Figure 3.4 Difference between Umbrella Trial and Basket Trial Designs
  • Figure 3.5 Process of Generating Evidence from Real World Data
  • Figure 3.6 Patient Centric Approach to Clinical Trials
  • Figure 3.7 Role of Big Data in Clinical Research
  • Figure 4.1 Virtual Clinical Trial Service Providers: Distribution by Year of Establishment
  • Figure 4.2 Virtual Clinical Trial Service Providers: Distribution by Company Size
  • Figure 4.3 Virtual Clinical Trial Service Providers: Distribution by Location of Headquarters
  • Figure 4.4 Virtual Clinical Trial Service Providers: Distribution by Year of Establishment and Company Size
  • Figure 4.5 Virtual Clinical Trial Service Providers: Distribution by Type of Service Offered
  • Figure 4.6 Virtual Clinical Trial Service Providers: Distribution by Company Size and Type of Service Offered
  • Figure 4.7 Virtual Clinical Trial Service Providers: Distribution by Number of Services Offered
  • Figure 5.1 Cambridge Cognition: Annual Revenues, 2016-H1 2020 (GBP Million)
  • Figure 5.2 IQVIA: Annual Revenues, 2017-2019 (USD Billion)
  • Figure 6.1 Virtual Clinical trial related Initiatives of Big Pharma Players: Timeline of Events
  • Figure 7.1 Key Attributes of Virtual CROs
  • Figure 7.2 Transition from Traditional CRO to Virtual CRO
  • Figure 8.1 Funding and Investment Analysis: Cumulative Number of Instances by Year, 2014-2020
  • Figure 8.2 Funding and Investment Analysis: Cumulative Amount Invested, 2014-2020 (USD Million)
  • Figure 8.3 Funding and Investment Analysis: Distribution of Number of Instances by Type of Funding, 2014-2020
  • Figure 8.4 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, 2014-2020 (USD Million)
  • Figure 8.5 Funding and Investment Analysis: Most Active Players, 2014-2020 (USD Million)
  • Figure 8.6 Funding and Investment Analysis: Most Active Investors
  • Figure 8.7 Funding and Investment Analysis: Distribution by Geography
  • Figure 8.8 Funding and Investment Analysis: Concluding Remarks
  • Figure 9.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-2020
  • Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2014-2020
  • Figure 9.4 Partnerships and Collaborations: Distribution by Focus Area Mentioned in the Agreement
  • Figure 9.5 Partnerships and Collaborations: Distribution by Target Therapeutic Area
  • Figure 9.6 Partnerships and Collaborations: Distribution by Year and Type of Partner
  • Figure 9.7 Partnerships and Collaborations: Most Active Players
  • Figure 9.8 Partnership and Collaborations: Regional Distribution
  • Figure 9.9 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Figure 10.1 COVID-19 Impact on Clinical Research
  • Figure 10.2 Virtual Clinical Trial Service Providers Market, 2020-2050: COVID Impact Scenario (USD Billion)
  • Figure 11.1 Clinical Trial Analysis: Distribution by Trial Registration Year
  • Figure 11.2 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year
  • Figure 11.3 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 11.4 Clinical Trial Analysis: Distribution by Type of Sponsor
  • Figure 11.5 Clinical Trial Analysis: Distribution by Target Therapeutic Area
  • Figure 11.6 Clinical Trial Analysis: Distribution by Target Indication
  • Figure 11.7 Clinical Trial Analysis: Distribution by Study Design
  • Figure 11.8 Clinical Trial Analysis: Most Active Players
  • Figure 11.9 Clinical Trial Analysis: Distribution by Number of Trials and Geographical Location
  • Figure 11.10 Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Geographical Location
  • Figure 11.11 Clinical Trial Analysis: Distribution by Enrolled Patient Population, Trial Status and Geographical Location
  • Figure 12.1 Virtual Clinical Trial Service Providers Market Opportunity, 2020-2050 (USD Billion)
  • Figure 12.2 Virtual Clinical Trial Service Providers Market Opportunity, 2020 and 2050: Distribution by Therapeutic Area (USD Billion)
  • Figure 12.3 Virtual Clinical Trial Service Providers Market Opportunity, 2020 and 2050: Distribution by Phase of Development (USD Billion)
  • Figure 12.4 Virtual Clinical Trial Service Providers Market Opportunity, 2020 and 2050: Distribution by Geography (USD Billion)
  • Figure 12.5 Virtual Clinical Trial Services Market in North America, 2020-2050 (USD Billion)
  • Figure 12.6 Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050 (USD Million)
  • Figure 12.7 Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
  • Figure 12.8 Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
  • Figure 12.9 Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
  • Figure 12.10 Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
  • Figure 12.11 Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050 (USD Million)
  • Figure 12.12 Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
  • Figure 12.13 Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
  • Figure 12.14 Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
  • Figure 12.15 Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
  • Figure 12.16 Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050 (USD Million)
  • Figure 12.17 Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
  • Figure 12.18 Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
  • Figure 12.19 Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
  • Figure 12.20 Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
  • Figure 12.21 Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050 (USD Million)
  • Figure 12.22 Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
  • Figure 12.23 Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
  • Figure 12.24 Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
  • Figure 12.25 Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
  • Figure 12.26 Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050 (USD Million)
  • Figure 12.27 Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
  • Figure 12.28 Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
  • Figure 12.29 Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
  • Figure 12.30 Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
  • Figure 12.31 Virtual Clinical Trial Services Market for Respiratory Disorders in North America, 2020-2050 (USD Million)
  • Figure 12.32 Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
  • Figure 12.33 Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
  • Figure 12.34 Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
  • Figure 12.35 Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
  • Figure 12.36 Virtual Clinical Trial Services Market for Other Therapeutic Areas in North America, 2020-2050 (USD Million)
  • Figure 12.37 Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase I Studies (USD Million)
  • Figure 12.38 Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase II Studies (USD Million)
  • Figure 12.39 Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase III Studies (USD Million)
  • Figure 12.40 Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase IV Studies (USD Million)
  • Figure 12.41 Virtual Clinical Trial Services Market Opportunity in Europe, 2020-2050 (USD Billion)
  • Figure 12.42 Virtual Clinical Trial Services Market Opportunity for Cardiovascular Disorders in Europe, 2020-2050 (USD Million)
  • Figure 12.43 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
  • Figure 12.44 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
  • Figure 12.45 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
  • Figure 12.46 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
  • Figure 12.47 Virtual Clinical Trial Services Market Opportunity for Infectious Disorders in Europe, 2020-2050 (USD Million)
  • Figure 12.48 Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
  • Figure 12.49 Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
  • Figure 12.50 Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
  • Figure 12.51 Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
  • Figure 12.52 Virtual Clinical Trial Services Market Opportunity for Metabolic Disorders in Europe, 2020-2050 (USD Million)
  • Figure 12.53 Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
  • Figure 12.54 Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
  • Figure 12.55 Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
  • Figure 12.56 Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
  • Figure 12.57 Virtual Clinical Trial Services Market Opportunity for Neurological Disorders in Europe, 2020-2050 (USD Million)
  • Figure 12.58 Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
  • Figure 12.59 Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
  • Figure 12.60 Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
  • Figure 12.61 Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
  • Figure 12.62 Virtual Clinical Trial Services Market Opportunity for Oncological Disorders in Europe, 2020-2050 (USD Million)
  • Figure 12.63 Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
  • Figure 12.64 Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
  • Figure 12.65 Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
  • Figure 12.66 Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
  • Figure 12.67 Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in Europe, 2020-2050 (USD Million)
  • Figure 12.68 Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
  • Figure 12.69 Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
  • Figure 12.70 Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
  • Figure 12.71 Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
  • Figure 12.72 Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in Europe, 2020-2050 (USD Billion)
  • Figure 12.73 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase I Studies (USD Million)
  • Figure 12.74 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase II Studies (USD Million)
  • Figure 12.75 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase III Studies (USD Million)
  • Figure 12.76 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
  • Figure 12.77 Virtual Clinical Trial Services Market Opportunity in Asia Pacific 2020-2050 (USD Billion)
  • Figure 12.78 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050 (USD Million)
  • Figure 12.79 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
  • Figure 12.80 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
  • Figure 12.81 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
  • Figure 12.82 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
  • Figure 12.83 Virtual Clinical Trial Service Providers Market Opportunity for Infectious Disorders in Asia-Pacific, 2020-2050 (USD Million)
  • Figure 12.84 Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
  • Figure 12.85 Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
  • Figure 12.86 Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
  • Figure 12.87 Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
  • Figure 12.88 Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050 (USD Million)
  • Figure 12.89 Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
  • Figure 12.90 Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
  • Figure 12.91 Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
  • Figure 12.92 Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
  • Figure 12.93 Virtual Clinical Trial Service Providers Market Opportunity for Neurological Disorders in Asia-Pacific, 2020-2050 (USD Million)
  • Figure 12.94 Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
  • Figure 12.95 Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
  • Figure 12.96 Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
  • Figure 12.97 Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
  • Figure 12.98 Virtual Clinical Trial Services Market Opportunity for Oncological Disorders in Asia-Pacific, 2020-2050 (USD Million)
  • Figure 12.99 Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
  • Figure 12.100 Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
  • Figure 12.101 Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
  • Figure 12.102 Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
  • Figure 12.103 Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in Asia-Pacific, 2020-2050 (USD Million)
  • Figure 12.104 Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
  • Figure 12.105 Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
  • Figure 12.106 Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
  • Figure 12.107 Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
  • Figure 12.108 Virtual Clinical Trial Service Providers Market Opportunity for Other Therapeutic Areas in Asia-Pacific, 2020-2050 (USD Million)
  • Figure 12.109 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
  • Figure 12.110 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
  • Figure 12.111 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
  • Figure 12.112 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
  • Figure 12.113 Virtual Clinical Trial Services Market Opportunity in Rest of the World, 2020-2050 (USD Million)
  • Figure 12.114 Virtual Clinical Trial Service Market for Cardiovascular Disorders in Rest of the World, 2020-2050 (USD Million)
  • Figure 12.115 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
  • Figure 12.116 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
  • Figure 12.117 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
  • Figure 12.118 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
  • Figure 12.119 Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050 (USD Million)
  • Figure 12.120 Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
  • Figure 12.121 Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
  • Figure 12.122 Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
  • Figure 12.123 Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
  • Figure 12.124 Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050 (USD Million)
  • Figure 12.125 Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
  • Figure 12.126 Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
  • Figure 12.127 Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
  • Figure 12.128 Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
  • Figure 12.129 Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050 (USD Million)
  • Figure 12.130 Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
  • Figure 12.131 Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
  • Figure 12.132 Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
  • Figure 12.133 Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
  • Figure 12.134 Virtual Clinical Trial Service Providers Market Opportunity for Oncological Disorders in Rest of the World, 2020-2050 (USD Million)
  • Figure 12.135 Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
  • Figure 12.136 Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
  • Figure 12.137 Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
  • Figure 12.138 Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
  • Figure 12.139 Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050 (USD Million)
  • Figure 12.140 Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
  • Figure 12.141 Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
  • Figure 12.142 Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
  • Figure 12.143 Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
  • Figure 12.144 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050 (USD Million)
  • Figure 12.145 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
  • Figure 12.146 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
  • Figure 12.147 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
  • Figure 12.148 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
  • Figure 13.1 Concluding Remarks: Current Market Landscape
  • Figure 13.2 Concluding Remarks: Key Application Areas
  • Figure 13.3 Concluding Remarks: Partnerships and Collaborations
  • Figure 13.4 Concluding Remarks: Clinical Trial Analysis
  • Figure 13.5 Concluding Remarks: Market Sizing and Opportunity Analysis